Genmab’s Bispecific Antibodies Catch Another Big Fish

17/08/2015 - 2 minutes

Genmab, the Danish company developing the DuoBody technology platform to create and develop bispecific antibody candidates, just signed another licensing agreement with a Big Pharma company. This time, Novo Nordisk has been caught in a potential $502 million (€453m) deal.

The DuoBody technology involves three basic steps to generate stable bispecific human IgG1 antibodies. In the first step, two IgG1s, each containing single matched mutations in the third constant (CH3) domain, are produced separately using standard mammalian recombinant cell lines (step 1 on the following figure). Subsequently, these IgG1 antibodies are purified according to standard processes (step 2) and then recombined in a bispecific antibody product with a very high yield (typically >95%) (step 3).

 

To date, Genmab has licensed the DuoBody technology to 7 companies including Novartis, Janssen, Kyowa Hakko Kirin, Eli Lilly, Cormorant, Agenus and an undisclosed major biotech.

Novartis licensed the DuoBody technology with options to commercialize two bispecific programs in a deal signed in June 2012 that included an upfront payment of $2 million (€1,8m) with a total potential deal value of $175 million (€158m) plus research funding and royalties.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!